Supernus Q3 revenue $175.7M (+14% YoY); raises FY guidance; Qelbree sales +68%

SUPERNUS PHARMACEUTICALS, INC.

2024-Q3 EPS reported $1.05 revenue$487,658,000

Net sales of Qelbree $62.4M (+68% YoY); GOCOVRI $35.6M (+8% YoY) in Q3 2024.
Total revenue $175.7M (+14% YoY); operating earnings $40.9M; adjusted operating earnings $67.7M.
Raising full year 2024 guidance for total revenues and operating earnings (GAAP and Non-GAAP).
SPN-820 Phase 2a in MDD: rapid decrease in depressive symptoms, 80% decrease in suicidal ideation; Phase 2b data H1 2025.
SPN-817 Phase 2a in treatment-resistant seizures: 56% median seizure reduction; Phase 2b expected start by end 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.